GLP-1 Weight Loss Medications in 2026: Ozempic, Zepbound & Beyond

A clinician-reviewed 2026 breakdown of GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, Zepbound — plus the new oral pills reshaping medical weight loss.

The GLP-1 Revolution Is Just Getting Started

GLP-1 receptor agonists have become the most transformative class of medical weight loss drugs since bariatric surgery. In 2026, three new oral GLP-1 pills — including orforglipron and a next-gen semaglutide tablet — are joining injectable staples like Ozempic (semaglutide), Wegovy, Mounjaro (tirzepatide), and Zepbound.

How GLP-1s Work

GLP-1 agonists mimic a gut hormone that:

• Slows gastric emptying (you feel full longer)
• Signals satiety to the hypothalamus
• Improves insulin sensitivity and blood sugar
• Reduces "food noise" — the constant background craving

2026 Comparison

Drug	Class	Weekly Loss	Avg 68-Wk Loss
Wegovy (semaglutide 2.4mg)	GLP-1	~0.5%	14.9%
Zepbound (tirzepatide)	GLP-1 + GIP	~0.7%	22.5%
Retatrutide (2026)	GLP-1/GIP/glucagon	~0.9%	24%+

Side Effects & Monitoring

Nausea, constipation, and rare pancreatitis remain the main concerns. Home monitoring with a pulse oximeter and blood pressure cuff is recommended for patients with cardiopulmonary comorbidities. Sleep apnea often improves dramatically with weight loss — many patients can lower CPAP pressure within 6 months. Talk to your sleep doctor before adjusting your CPAP machine settings.

Questions about pairing weight loss with respiratory therapy? Call (877) 699-4365.